Viridian Therapeutics, Inc. · NASDAQ:VRDN

Viridian Therapeutics — Technical Presentation (May 2026)

20 slides from Viridian Therapeutics's technical presentation, May 5, 2026

  1. Slide 1: Elegrobart REVEAL-2 Topline Results

    Elegrobart REVEAL-2 Topline Results May 5, 2026

  2. Slide 2: Cautionary note regarding forward-looking statements

    Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “mi

  3. Slide 3: Agenda

    Agenda Steve Mahoney Introduction President & Chief Executive Officer Radhika Tripuraneni, MD REVEAL-2 Phase 3 Topline Results Chief Medical Officer Steve Mahoney Closing Remarks President & Chief Executive Officer Steve Mahoney, President & Chief Executive Officer Radhika Tripuraneni, MD, Chief Med

  4. Slide 4: Viridian is developing an IGF-1R antibody franchise with the potential to transform the treatment of patients with TED

    Viridian is developing an IGF-1R antibody franchise with the potential to transform the treatment of patients with TED Elegrobart Veligrotug Teprotumumab Potential to be the first subcutaneous autoinjector in TED Steroids/Surgery Next-gen anti-IGF-1R: Breakthrough Q4W or Q8W First approved self-admi

  5. Slide 5: REVEAL-2 topline results in chronic TED build on positive elegrobart clinical profile observed in REVEAL-1

    REVEAL-2 topline results in chronic TED build on positive elegrobart clinical profile observed in REVEAL-1  Achieved primary endpoint with high statistical significance  Clinically meaningful outcomes Topline data today on multiple secondary endpoints, across both Q4W and Q8W doses  Rapid onset o

  6. Slide 6: REVEAL-2 in chronic TED patients met primary and multiple secondary endpoints and elegrobart was generally well tolerated

    REVEAL-2 in chronic TED patients met primary and multiple secondary endpoints and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001), with IV-like proptosis response – 50% of Q4W and 54% of Q8W achieved a proptosis response vs 15% pl

  7. Slide 7: REVEAL-2 is a phase 3 randomized, controlled, double-masked trial of elegrobart in chronic TED

    REVEAL-2 is a phase 3 randomized, controlled, double-masked trial of elegrobart in chronic TED Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) Treatment Arms D11 W4 W8 W12 W16 W20 W24 Follow-up (1:1:1) through W52 Primary Endpoint Elegrobart Q4W1 Analysis Primary efficacy endp

  8. Slide 8: REVEAL-2 is the largest pivotal clinical trial conducted in chronic TED to date

    REVEAL-2 is the largest pivotal clinical trial conducted in chronic TED to date Randomized Patients (n = 204) Elegrobart Q4W Elegrobart Q8W Placebo (n = 70) (n = 68) (n = 66) Discontinued Discontinued Discontinued • 3 withdrawal of consent • 1 withdrawal of consent • 2 withdrawal of consent • 2 TEAE

  9. Slide 9: REVEAL-2 baseline characteristics were well-balanced between arms

    REVEAL-2 baseline characteristics were well-balanced between arms 7.8 Elegrobart Q4W Elegrobart Q8W Placebo (n = 70) (n = 68) (n = 66) Age in years, mean (SD) 50.1 (11.3) 52.0 (11.2) 53.3 (11.2) Participant Female sex, n (%) 60 (86%) 57 (84%) 53 (80%) Demographics White race, n (%) 54 (77%) 52 (76%)

  10. Slide 10: REVEAL-2 achieved high statistical significance on primary endpoint and multiple secondary endpoints at 24 weeks

    REVEAL-2 achieved high statistical significance on primary endpoint and multiple secondary endpoints at 24 weeks Elegrobart Elegrobart Placebo Q4W Q8W (n = 66) (n = 70) (n = 68) FDA Primary Endpoint 50% 54% Proptosis responder rate (PRR)1,2 15% (p < 0.0001) (p < 0.0001) EMA Primary Proptosis Endpoin

  11. Slide 11: Significant proptosis responder rate at all time points after week 4 in both treatment arms

    Significant proptosis responder rate at all time points after week 4 in both treatment arms Proptosis Responder Rate – Q4W Proptosis Responder Rate – Q8W Primary Key secondary 100 endpoint: 100 endpoint: p < 0.0001 p < 0.0001 Proptosis Responder Rate (%) Proptosis Responder Rate (%) 80 80 54% 60 50%

  12. Slide 12: Significant proptosis mean change from baseline at all time points across both treatment arms, including at week 4

    Significant proptosis mean change from baseline at all time points across both treatment arms, including at week 4 Mean Change from Baseline – Q4W Mean Change from Baseline – Q8W Key secondary Key secondary endpoint: endpoint: p < 0.0001 0 p < 0.0001 0 -0.27 -0.27 -0.52 -0.52 -0.56 -0.61 -0.56 -0.61

  13. Slide 13: First demonstration of statistically significant diplopia response for a subcutaneous treatment in chronic TED

    First demonstration of statistically significant diplopia response for a subcutaneous treatment in chronic TED Diplopia Responder Rate – Q4W Diplopia Complete Resolution – Q4W Key secondary Key secondary 100 100 endpoint: endpoint: p = 0.0118 p = 0.0295 80 80 Diplopia Resolution Rate (%) Diplopia Re

  14. Slide 14: Proptosis & diplopia benefit demonstrated in low-CAS subgroup

    Proptosis & diplopia benefit demonstrated in low-CAS subgroup Key efficacy endpoints in subgroup of patients with Elegrobart Elegrobart low CAS (CAS ≤ 1) at baseline Placebo Q4W Q8W (n = 16) Same CAS inclusion criteria as teprotumumab chronic TED phase 4 study1 (n = 17) (n = 15) 54% 55% Proptosis re

  15. Slide 15: Elegrobart was generally well tolerated through week 24

    Elegrobart was generally well tolerated through week 24 Elegrobart Q4W Elegrobart Q8W Placebo N=70 N=68 N=66 n (%) n (%) n (%) Participants with any treatment-emergent 55 (79%) 56 (82%) 44 (67%) adverse event (TEAE) Participants with any serious AE (SAE) 3 (4%) 1 (1%) 0 Participants with any treatme

  16. Slide 16: AE categories for elegrobart in REVEAL-2 were consistent with those generally expected from the anti-IGF-1R class

    AE categories for elegrobart in REVEAL-2 were consistent with those generally expected from the anti-IGF-1R class Elegrobart Q4W Elegrobart Q8W Placebo AEs occurring at ≥10% frequency in any arm N=70 N=68 N=66 n (%) n (%) n (%) Muscle spasms 15 (21%) 25 (37%) 7 (11%) Injection site reactions (ISR)1,

  17. Slide 17: REVEAL-2 in chronic TED patients met primary and multiple secondary endpoints and elegrobart was generally well tolerated

    REVEAL-2 in chronic TED patients met primary and multiple secondary endpoints and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001), with IV-like proptosis response – 50% of Q4W and 54% of Q8W achieved a proptosis response vs 15% pl

  18. Slide 18: Elegrobart topline data & profile support its potential to transform TED treatment with BLA submission anticipated in Q1 2027

    Elegrobart topline data & profile support its potential to transform TED treatment with BLA submission anticipated in Q1 2027 Only SC program with positive data in both Potential to be the first active and chronic TED pivotal clinical trials subcutaneous autoinjector in TED Elegrobart’s two pivotal

  19. Slide 19: Viridian has the potential to provide multiple differentiated treatment solutions for TED patients in one portfolio

    Viridian has the potential to provide multiple differentiated treatment solutions for TED patients in one portfolio Veligrotug Elegrobart Elegrobart Q4W Q8W Granted Breakthrough Potential to be the first subcutaneous Therapy Designation & autoinjector in TED, providing a simple, Priority Review from

  20. Slide 20: Thank you to the TED community

    Thank you to the TED community: patients, advocates, investigators, research staff, and partners who made this trial a success

Viridian Therapeutics — Technical Presentation (May 2026) on 6ix